Terconazole warnings and precautions
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Warnings
Anaphylaxis and toxic epidermal necrolysis have been reported during terconazole therapy. TERAZOL® therapy should be discontinued if anaphylaxis or toxic epidermal necrolysis develops.
Precautions
General
Discontinue use and do not retreat with terconazole if sensitization, irritation, fever, chills or flu-like symptoms are reported during use.
The base contained in the suppository formulation may interact with certain rubber or latex products, such as those used in vaginal contraceptive diaphragms; therefore concurrent use is not recommended[1]
References
Adapted from the FDA Package Insert.